Drugs / 3,4-methylenedioxyamphetamine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT00823407 | Jan → Jul 2009 | — | California Pacific Medical Center Research Institute | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 3,4-methylenedioxyamphetamine | “We investigated the mechanisms of hallucinogen-induced visions by measuring the visual and perceptual effects of the hallucinogenic serotonin 5-HT2AR receptor agonist and...” PMID 21152030 ↗ Dec 2010 |
| Known as | MDA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00823407 ↗ |
| Action | Activate | “the hallucinogenic serotonin 5-HT2AR receptor agonist” PMID 21152030 ↗ Dec 2010 |
| Route | Oral | “single oral dose of MDA” NCT00823407 ↗ |